Tarsus is developing its lead candidate TP-03, potentially the first FDA-approved therapy for Demodex blepharitis, and a pipeline of investigational therapies targeting eye care, dermatology ...

This article highlights clinical and economic factors associated with Demodex blepharitis as well as diagnostic complexities, limitations of traditional therapies, the safety and efficacy of the 1 ...